341607

PD 173074

≥97% (HPLC), FGF and VEGF receptor inhibitor, solid

• Synonym(e): FGF/VEGF Receptor Tyrosine Kinase Inhibitor, PD173074, 1- t-Butyl-3-(6-(3,5-dimethoxyphenyl)-2-(4-diethylaminobutylamino)-pyrido[2,3-d]pyrimidin-7-yl)urea, PD173074, VEGFR Tyrosine Kinase Inhibitor XXIII, VEGFR2 Kinase Inhibitor XX, 1-t-Butyl-3-(6-(3,5-dimethoxyphenyl)-2-(4-diethylaminobutylamino)-pyrido[2,3-d]pyrimidin-7-yl)urea, PD173074, VEGFR Tyrosine Kinase Inhibitor XXIII, VEGFR2 Kinase Inhibitor XX
• Empirische Formel (Hill-System): C₂₈H₄₁N₇O₃
• CAS-Nummer: 219580-11-7
• Molekulargewicht: 523.67
• UNSPSC Code: 12352200
• NACRES: NA.77
• MDL number: MFCD08705327
• Assay: ≥97% (HPLC)
• Form: solid
• Storage condition: OK to freeze, protect from light

Eigenschaften

• Produktname: FGF/VEGF Receptor Tyrosine Kinase Inhibitor, PD173074, The FGF/VEGF Receptor Tyrosine Kinase Inhibitor, PD173074 controls the biological activity of FGF/VEGF Receptor Tyrosine Kinase. Primarily used for Phosphorylation & Dephosphorylation applications.
• Quality Segment: 100
• assay: ≥97% (HPLC)
• form: solid
• manufacturer/tradename: Calbiochem^®
• storage condition: OK to freeze, protect from light
• color: yellow
• solubility: DMSO: 100 mg/mL
• shipped in: ambient
• storage temp.: 2-8°C
• SMILES string: N(CCCCNc1nc2nc(c(cc2cn1)c3cc(cc(c3)OC)OC)NC(=O)NC(C)(C)C)(CC)CC
• InChI: 1S/C28H41N7O3/c1-8-35(9-2)13-11-10-12-29-26-30-18-20-16-23(19-14-21(37-6)17-22(15-19)38-7)25(31-24(20)32-26)33-27(36)34-28(3,4)5/h14-18H,8-13H2,1-7H3,(H3,29,30,31,32,33,34,36)
• InChI key: DXCUKNQANPLTEJ-UHFFFAOYSA-N

Beschreibung

General description

A cell-permeable pyridopyrimidine compound that acts as a potent, ATP-competitive, and reversible inhibitor of FGF and VEGF receptors (IC₅₀ = 21.5 nM for FGFR1). It inhibits PDGFR and c-Src only at much higher concentration (IC₅₀ = 17.6 µM, 19.8 µM, respectively) and exhibits little effect against EGFR, InsR, MEK, and cPKC even at concentrations as high as 50 µM. Shown to inhibit the autophosphorylation of endogenous FGFR1 (IC₅₀<5 nM) and overexpressed VEGFR2 (IC₅₀<200 nM) in NIH3T3 cells in vitro, and FGF- and VEGF-induced angiogenesis in mice in vivo.

Packaging

Packaged under inert gas

Preparation Note

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.

Other Notes

Koziczak, M., et al. 2004. Oncogene23, 3501.
Trudel, S., et al. 2004. Blood103, 3521.
Skaper, S.D., et al. 2000. J. Neurochem.75, 1520.
Mohammadi, M., et al. 1998. EMBO J.17, 5896.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Toxicity: Irritant (B)

Sicherheitshinweise

• Lagerklasse: 11 - Combustible Solids
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable